Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT
| FULL TEXT
PROactive: time for a critical appraisal
Betteridge et al.
Eur Heart J 2008;29:969-983.
ABSTRACT
| FULL TEXT
From individual risk factors and the metabolic syndrome to global cardiometabolic risk
Despres et al.
Eur Heart J Suppl 2008;10:B24-B33.
ABSTRACT
| FULL TEXT
Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Goldenberg et al.
J Am Coll Cardiol 2008;51:459-465.
ABSTRACT
| FULL TEXT
Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter and Rye
Arterioscler. Thromb. Vasc. Bio. 2008;28:39-46.
ABSTRACT
| FULL TEXT
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT
Update on Dyslipidemia
Garg and Simha
J. Clin. Endocrinol. Metab. 2007;92:1581-1589.
ABSTRACT
| FULL TEXT
Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets
Lee and Choudhury
Heart 2007;93:559-564.
ABSTRACT
| FULL TEXT
Hypertriglyceridemia: its etiology, effects and treatment
Yuan et al.
CMAJ 2007;176:1113-1120.
ABSTRACT
| FULL TEXT
Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction
Grant and Meigs
Diabetes Care 2007;30:479-484.
ABSTRACT
| FULL TEXT
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown and Plutzky
Circulation 2007;115:518-533.
ABSTRACT
| FULL TEXT
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik et al.
Pharmacol. Rev. 2006;58:726-741.
ABSTRACT
| FULL TEXT
Multitherapy for diabetes
Menard and Ardilouze
CMAJ 2006;175:1247-1247.
FULL TEXT
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch
CJASN 2006;1:1090-1099.
ABSTRACT
| FULL TEXT
Exogenous Insulin Use and Hypertension in Adult Patients With Type 2 Diabetes Mellitus.
Tseng
Arch Intern Med 2006;166:1184-1189.
ABSTRACT
| FULL TEXT
Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes
McQueen
Evid. Based Med. 2006;11:86-86.
FULL TEXT
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Costa et al.
BMJ 2006;332:1115-1124.
ABSTRACT
| FULL TEXT
The role of fibrates in a statin world.
Bloomfield
Arch Intern Med 2006;166:715-716.
FULL TEXT
Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study.
Tenkanen et al.
Arch Intern Med 2006;166:743-748.
ABSTRACT
| FULL TEXT
Differential Effects of Isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the Activation of PPAR{alpha}, PPAR{gamma}, and Adipocyte Differentiation In Vitro
Shen et al.
J. Nutr. 2006;136:899-905.
ABSTRACT
| FULL TEXT
Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?
Barter and Rye
Circulation 2006;113:1553-1555.
FULL TEXT
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia
Reeds et al.
Am. J. Physiol. Endocrinol. Metab. 2006;290:E47-E53.
ABSTRACT
| FULL TEXT
The Other Side of the Bezafibrate Infarction Prevention Trial Data--Reply
Tenenbaum et al.
Arch Intern Med 2005;165:2432-2432.
FULL TEXT
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT
Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture
Gotto
J Am Coll Cardiol 2005;46:1219-1224.
FULL TEXT
Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches
Bloomgarden
Diabetes Care 2005;28:2073-2080.
FULL TEXT
Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists
Staels and Fruchart
Diabetes 2005;54:2460-2470.
ABSTRACT
| FULL TEXT
Raising HDL-cholesterol and lowering CHD risk: does intervention work?
Shepherd
Eur Heart J Suppl 2005;7:F15-F22.
ABSTRACT
| FULL TEXT
Niaspan(R): a powerful treatment option for 'diabetic dyslipidaemia'
Reasner
Eur Heart J Suppl 2005;7:F48-F55.
ABSTRACT
| FULL TEXT
Strategies for the prevention of type 2 diabetes and cardiovascular disease
Tuomilehto et al.
Eur Heart J Suppl 2005;7:D18-D22.
FULL TEXT
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Tenenbaum et al.
Arch Intern Med 2005;165:1154-1160.
ABSTRACT
| FULL TEXT
Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?
Drexel et al.
Diabetes Care 2005;28:101-107.
ABSTRACT
| FULL TEXT
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT
Nuclear Receptor Signaling and Cardiac Energetics
Huss and Kelly
Circ. Res. 2004;95:568-578.
ABSTRACT
| FULL TEXT
Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'
Chew and Watts
QJM 2004;97:537-548.
ABSTRACT
| FULL TEXT
The Relationship of Fasting Serum Radioimmune Insulin Levels to Incident Coronary Heart Disease in an Insulin-Treated Diabetic Cohort
Kronmal et al.
J. Clin. Endocrinol. Metab. 2004;89:2852-2858.
ABSTRACT
| FULL TEXT
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss
Diabetes Care 2004;27:1496-1504.
ABSTRACT
| FULL TEXT
Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians
Snow et al.
ANN INTERN MED 2004;140:644-649.
ABSTRACT
| FULL TEXT
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Vijan and Hayward
ANN INTERN MED 2004;140:650-658.
ABSTRACT
| FULL TEXT
A Novel Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis
Guo et al.
Endocrinology 2004;145:1640-1648.
ABSTRACT
| FULL TEXT
Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant
J Clin Pharmacol 2004;44:423-430.
ABSTRACT
| FULL TEXT
Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)
Robins et al.
Diabetes Care 2003;26:1513-1517.
ABSTRACT
| FULL TEXT
Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome
Despres et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:702-703.
FULL TEXT